This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Investors Chronicle page 28..

The New Blockbusters.

Tiny technology management group MMI has developed a range of cancer compounds from the metal Ruthenium through its "Baby Bio" company Oncosense.
"Platinum was a blockbuster drug with $5 billion sales and one of the most commonly used cancer drugs" said David Best
"We have 16 Ruthenium compounds that actually work better than Platinum".
Oncosense is also working on cancer drugs developed from Pineapple.And MMI through a joint venture with Southampton University, is developing a cancer vaccine that fools the body into thinking cancer cells are tetanus.
While the cancer market is compelling, though, remember thatit is highly risky.There is a high failure rate with many drugs still failing phase 3 trials.This is because it is difficult to replicate human cancer in pre-clinical models.

Moved up 3p last week and over 3p today so things are looking up..a possible 10 bagger according to IC but I would be happy with 200p in 12 months time.

Yup read that in the IC. Things look good for this year.

cheers GF.

Looks like we have pushed through an upper resistance level on the chart, will be topping up in the morning................... good vibes for the new year.......... Cheers..... Rob

News is immiment could be Friday or Monday...hold on.

Yup and it could be mind blowing from what I have heard.

cheers GF.

This will be my only exciting one of the fortnight - it's like watching paint dry the rest of the market. Should pay for my next holiday:)

presently up 2p but I reckon it has much further to go judging by the amount of speculative buying the last few days..the cancer oncology market is expected to hit $60 billion in the next 5 years..

Good Evening Gentlemen

Have just arrived home and noted today's trades and mark - up.

GF & Mitzy where anticipating news today or monday...... did this happen today? I have stated previously that I consider MMG as potentially the most explosive equity around. I am a long term holder and continue to top up at every dip, my portfolio is weighted heavily toward this co.

Monday will be interesting.. good luck guy's

By the way is anybody watching Dmatek (DTK).
It is an Israeli company that specialises in electronic tagging. I first bought this some years ago and made a nice profit as a result of it riding the 'tech boom'. more recently it has settled to an appropriate price and I have re-bought and made a 40 p/c gain in the last few months.
If you consider the potential of 'tagging' , not only for monitoring criminals but also for child protection the potential is massive. They have a constant feed of good news and orders.
I have posted on this thread because I hope that the likes of Goldfinger & Mitzy, who I know visit this thread, have guided me toward Hamworthy and Paypoint (many thanks) may benefit from this share.

Good luck guys............ Rob

No news today Rob but plenty of action this week and I hope next week too.MACD is showing a buy signal and so is DMI.Could see further rises this coming week if we do get the news we are waiting for..cheers.

Will be an interesting week I feel.

cheers GF.

A positive opening.

cheers GF.

What is mind-blowing is waiting for this news, we've been waiting since September, I thought MMG said they had intentions to keep holders more informed!! Doesn't look like it and thats why sp is so crap for their portfolio and potential. Come on MMG, sell yourself better before people get bored.
I'm sure the institutions who keep lending out the loot want more progress before they spend again!!

Stay cool andy, its coming.

cheers GF.

MMG have been coming for ages, maybe they are developing a pill to last longer!!
Now that would have a good market!!! I'm still holding!!

Up 10% on the day and news to come soon...take my brokers word for it.Whatever you do dont get too impatient as the news will be good.

Blimey fella's. 10 p/cent. that is a nice welcome home tonight, hang in there.


Anybody hold Anglo Pacific???????????? have just hit 100 p/cent gain sell signal for me, I know you should keep to your strategy but this still looks like its going strong..... any comments welcome


Cheers. Rob

THIS IS JUST THE START GUYS, excelent news.

Medical Marketing Int'l Group PLC
28 January 2005


For Immediate Release 28 January 2005


MMI's ruthenium cancer therapy passes independently verified safety tests


Medical Marketing International Group plc (AIM:MMG), the Cambridge, UK-based
pharmaceutical development company today announces that lead ruthenium compounds
within its portfolio of cancer therapies show toxicity at an even safer level
than the safest cancer drug currently available, when tested in an industry
standard laboratory model.

Independent laboratory tests show ruthenium to have a low toxicity profile

Efficacy of ruthenium shown to be better than market-leading platinum drugs

Patents recently granted in biggest markets, USA and EU giving long patent
protection. Other patents are pending.


MMI has already shown that the ruthenium cancer therapies within its
wholly-owned subsidiary, Oncosense, appear in laboratory tests to be more
powerful than the platinum-based drugs which have been some of the most
successful cancer drugs for decades and which had peak sales of $5bn. Efficacy
of these compounds has also been independently demonstrated in both human cancer
cells and in vivo models. MMI recently announced that patents in USA and Europe,
the two biggest markets have been granted, and other patents are pending.

MMI used the Dundee-based specialist, CXR Biosciences Ltd to test the most
promising ruthenium compounds for potential toxicity. A summary of the CXR
results is announced today.


Mark Burton, Technical Manager at MMI said: 'We chose CXR because of their
highly regarded expertise in screening new drugs for harmful effects. Not only
did CXR deliver the results on time and on budget, they were able to show that
our ruthenium cancer therapies demonstrate a low toxicity profile. These
results, when added to the existing efficacy data show that ruthenium has great
clinical potential.'


Dr Cliff Elcombe Director at CXR and former Senior Scientist at Zeneca said: 'We
feel privileged to have been chosen by MMI to carry out the safety studies on
what now appears to be an extremely interesting new class of cancer drugs. The
safety screens that we performed indicate that this new group of cancer
therapies has enormous potential.'


Executive Chairman of MMI Group, David Best, commenting on these results said: '
Ruthenium is only one of MMI's portfolio of excellent drug candidates, but
already data show it to be potentially the most effective drug against serious
cancers like lung, colon and ovarian. This new data from CXR shows ruthenium to
be potentially relatively safe too. If these results are confirmed in the
clinical trials, then ruthenium may improve significantly on the standard
treatment for cancer patients and become a major commercial success in a cancer
therapy market that was worth $42 billion in 2004 and continues to grow in
double-digit figures.'


For further information, please contact:

David Best - Executive Chairman

cheers GF.

Added more MMG this one could be the share of the year, and blast away.

cheers GF.

Killicks name it as a company with potentially significant upside....! no sp predictions but I reckon they are advising their clients to buy up to 200p(my guess)..cheers.